doi:10.3969/j.issn.1004-583X.2023.02.015

Abstract

CLC Number:

R544.1

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.02.015

https://huicui.hebmu.edu.cn/EN/Y2023/V38/I2/181

References 21

[1]	Yin R, Yin L, Li L, et al. Hypertension in China: Burdens, guidelines and policy responses: A state-of-the-art review[J]. J Hum Hypertens, 2022, 36(2):126-134. doi: 10.1038/s41371-021-00570-z
[2]	中国医疗保健国际交流促进会高血压分会, 中国医师协会心血管分会, 中国高血压联盟, 等. 沙库巴曲缬沙坦在高血压患者临床应用的中国专家建议[J]. 中华高血压杂志, 2021, 29(2):108-114.
[3]	Unger T, Borghi C, Charchar F, et al. 2020 international society of hypertension global hypertension practice guidelines[J]. J Hypertens, 2020, 38(6):982-1004. doi: 10.1097/HJH.0000000000002453 pmid: 32371787
[4]	Miceli F, Presta V, Citoni B, et al. Conventional and new electrocardiographic criteria for hypertension-mediated cardiac organ damage: A narrative review[J]. J Clin Hypertens (Greenwich), 2019, 21(12):1863-1871. doi: 10.1111/jch.13726 pmid: 31693279
[5]	Konukoglu D, Uzun H. Endothelial dysfunction and hypertension[J]. J Adv Exp Med Biol, 2017, 956:511-540.
[6]	Gkaliagkousi E, Gavriilaki E, Triantafyllou A, et al. Clinical significance of endothelial dysfunction in essential hypertension[J]. J Curr Hypertens Rep, 2015, 17(11):85.
[7]	Ames MK, Atkins CE, Pitt B. The renin-angiotensin-aldosterone system and its suppression [published correction appears in J Vet Intern Med. 2019 Sep;33(5):2551][J]. J Vet Intern Med, 2019, 33(2):363-382. doi: 10.1111/jvim.15454 pmid: 30806496
[8]	Mattson DL. Immune mechanisms of salt-sensitive hypertension and renal end-organ damage[J]. J Nat Rev Nephrol, 2019, 15(5):290-300.
[9]	Cheung CY, Tay WT, Mitchell P, et al. Quantitative and qualitative retinal microvascular characteristics and blood pressure[J]. J Hypertens, 2011, 29(7):1380-1391. doi: 10.1097/HJH.0b013e328347266c pmid: 21558958
[10]	Dziedziak J, Zaleska-Żmijewska A, Szaflik JP, et al. Impact of arterial hypertension on the eye: A review of the pathogenesis, diagnostic methods, and treatment of hypertensive retinopathy[J]. J Med Sci Monit, 2022, 28:e935135.
[11]	McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11):993-1004. doi: 10.1056/NEJMoa1409077 URL
[12]	Kuwahara K. The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications[J]. J Pharmacol Ther, 2021, 227:107863. doi: 10.1016/j.pharmthera.2021.107863 URL
[13]	Corvol P. Le système rénine-angiotensine-aldostérone et son inhibition [The renin-angiotensin-aldosterone system and its suppression][J]. J Ann Pediatr (Paris), 1982, 29(9):657-658.
[14]	Kjeldsen SE, Narkiewicz K, Burnier M, et al. Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension?[J]. BloodPress, 2019, 28(2):75-76.
[15]	Yamamoto K, Rakugi H. Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment[J]. J Hypertens Res, 2021, 44(10):1239-1250.
[16]	Myhre PL, Prescott MF, Murphy SP, et al. Early B-type natriuretic peptide change in HFrEF patients treated with sacubitril/valsartan: A pooled analysis of EVALUATE-HF and PROVE-HF[J]. J JACC Heart Fail, 2022, 10(2):119-128.
[17]	Huo Y, Li W, Webb R, et al. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study[J]. J Clin Hypertens (Greenwich), 2019, 21(1):67-76. doi: 10.1111/jch.13437 pmid: 30536595
[18]	Writing Committee Members, Gulati M, Levy PD, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: A report of the American college of Cardiology/American heart association joint committee on clinical practice guidelines[J]. J Am Coll Cardiol, 2021, 78(22):e187-e285. doi: 10.1016/j.jacc.2021.07.053 URL
[19]	Williams B, Cockcroft JR, Kario K, et al. Effects of Sacubitril/Valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: The PARAMETER study[J]. J Hypertension, 2017, 69(3):411-420.
[20]	Kario K, Tamaki Y, Okino N, et al. LCZ696, a First-in-Class angiotensin Receptor-Neprilysin inhibitor: The first clinical experience in patients with severe hypertension[J]. J Clin Hypertens (Greenwich), 2016, 18(4):308-314. doi: 10.1111/jch.12667 pmid: 26402918
[21]	Writing Committee Members, ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure[J]. J Card Fail, 2022, 28(5):e1-e167. doi: 10.1016/j.cardfail.2022.02.010 pmid: 35378257

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 21

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liu Yi, Cui Kun, Liu Chang, Zhao Haotian, Li Li, Xue Hongyuan. Correlation between serum secreted frizzled-related protein 5 and early renal damage in patients with essential hypertension [J]. Clinical Focus, 2023, 38(12): 1073-1077.
[2]	Jiang Ji, Zhu Xiaogang, Jiang Shan, Dawa Zhaba, Cen Qiang. Risk factors of proteinuria in hypertensive people living at high altitude for generations [J]. Clinical Focus, 2023, 38(12): 1086-1090.
[3]	Xu Yang, Xue Ling. Influencing factors for mild cognitive impairment in type H hypertension patients combined with type 2 diabetes mellitus [J]. Clinical Focus, 2023, 38(10): 887-892.
[4]	. [J]. Clinical Focus, 2023, 38(1): 88-92.
[5]	Yin Yikun, Yin Xunwei, Wang Jialin, Sun Junzhi. Impacts of Tai Chi exercise cycle on blood pressure and cardiovascular risk factors in essential hypertension: a systematic review and meta-analysis [J]. Clinical Focus, 2022, 37(7): 599-606.
[6]	An Qinyan, Jiang Rong, Kang Bin, Du Ming, Zhou Renming, Zhao Hongjuan, Duan Yi, Lu Fei, Liu Jinming. Levels and clinical significance of RDW, NT-proBNP, BigET-1, HMGB1 in patients with idiopathic pulmonary arterial hypertension [J]. Clinical Focus, 2021, 36(11): 1001-1004.
[7]	. [J]. Clinical Focus, 2021, 36(8): 744-748.
[8]	Gong Tao, Hu Yueyuan, Gao Yun, Guo Chang, Shen Huinan, Wang Dongyu. Relationship between H-type hypertension and severity of neurological deficit in early acute cerebral infarction of LAA [J]. Clinical Focus, 2021, 36(7): 612-615.
[9]	. [J]. Clinical Focus, 2021, 36(6): 566-568.
[10]	. [J]. Clinical Focus, 2021, 36(3): 270-276.
[11]	Liu Xiaoteng, Shan Weichao, Hou Ruitian, Lin Jinping, Gao Yu, Jin Fengbiao, Liu Chang. Correlation between serum hypersensitive C-reactive protein, lipoprotein-related phospholipase A₂and senile essential hypertension complicated with type 2 diabetes [J]. Clinical Focus, 2021, 36(1): 25-29.
[12]	Liang Yuling, Li Wenxi, Gu Xuewen. Randomized controlled trial of Tianma Gouteng Decoction and irbesartan in treatment of essential hypertension [J]. Clinical Focus, 2020, 35(12): 1097-1100.
[13]	Zhu Bin;Wang Yongxia. Correlation between carotid plaque and blood pressure variation in patients with hypertension [J]. Clinical Focus, 2015, 30(12): 1360-1362.
[14]	Quan Feng;Fan Xuemei;Fang Wenlong. Clinical study of systemic lupus erythematosus associated pulmonary hypertension [J]. Clinical Focus, 2015, 30(12): 1402-1.40414e+007.
[15]	Wang Hongyi. Screening of secondary hypertension [J]. Clinical Focus, 2015, 30(11): 1202-1205.